Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial.

Published

Journal Article

OBJECTIVE: This study examined the prevalence and correlates of concomitant psychotropic medications and use of anticholinergic drugs to treat schizophrenia. METHODS: Concomitant medication use was studied at baseline for participants in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. RESULTS: Of the 1,380 patients with baseline medication data, 82 percent were taking psychotropic medications. Of this group, 6 percent were taking two antipsychotics (one first generation and one second generation); 38 percent, antidepressants; 22 percent, anxiolytics; 4 percent, lithium, and 15 percent, other mood stabilizers. The strongest predictors of taking several medications were having anxiety or depression, being female, and taking second-generation antipsychotics. Conversely, African Americans and those with better neurocognitive functioning were less likely to be taking several concomitant psychotropic medications. In some cases symptoms that were likely targets of polypharmacy, such as depression, remained prominent, suggesting only partial response. CONCLUSIONS: Concomitant use of psychotropic medications to treat people with schizophrenia is common. Empirical data demonstrating the effectiveness of many of these agents for this population are lacking.

Full Text

Duke Authors

Cited Authors

  • Chakos, MH; Glick, ID; Miller, AL; Hamner, MB; Miller, DD; Patel, JK; Tapp, A; Keefe, RSE; Rosenheck, RA

Published Date

  • August 2006

Published In

Volume / Issue

  • 57 / 8

Start / End Page

  • 1094 - 1101

PubMed ID

  • 16870959

Pubmed Central ID

  • 16870959

International Standard Serial Number (ISSN)

  • 1075-2730

Digital Object Identifier (DOI)

  • 10.1176/ps.2006.57.8.1094

Language

  • eng

Conference Location

  • United States